← Back to Search
Transcranial Magnetic Stimulation
TMS for Depression
Los Angeles, CA
N/A
Waitlist Available
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks (baseline and final visit)
Awards & highlights
No Placebo-Only Group
Summary
This trial will determine if a-rTMS at different frequencies can safely & tolerably treat Major Depressive Disorder. 30 participants will be tested over 2 weeks.
See full description
Who is the study for?
This trial is for adults aged 18-65 with moderate to severe Major Depressive Disorder, who haven't improved after trying at least two different types of antidepressants and psychotherapy. Participants must be able to commit to an accelerated treatment schedule but can't join if they have certain neurological conditions, risk of seizures, psychotic disorders, or magnetic-sensitive implants in their body.
What is being tested?
The study tests the safety and effectiveness of a non-standard frequency accelerated repetitive Transcranial Magnetic Stimulation (a-rTMS) on patients hospitalized with depression. It involves brain activity recordings, one MRI scan, determining individual TMS settings, daily symptom checks, and receiving 25 TMS treatments over up to two weeks.See study design
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site on the scalp, headache following treatment sessions or rarely seizures. Other less common side effects might involve lightheadedness or temporary hearing changes due to the noise during treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks (baseline and final visit)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks (baseline and final visit)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Treatment Efficacy as Measured by Change in Inventory of Depressive Symptoms (Self-Report) at Baseline and Final Visit
Secondary study objectives
Treatment Efficacy as Measured by Change in Patient Health Questionnaire-9 (PHQ-9) at Baseline and Final Visit.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Open-label TMSExperimental Treatment1 Intervention
Find a Location
Closest Location:UCLA TMS Service and Research Service· Los Angeles, CA
Who is running the clinical trial?
University of California, Los AngelesLead Sponsor
1,591 Previous Clinical Trials
10,425,729 Total Patients Enrolled
107 Trials studying Depression
50,230 Patients Enrolled for Depression
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have undergone psychotherapy for my depression.I am between 18 and 65 years old.I have an infection or poor skin condition on my scalp.I am at a higher risk of having seizures due to my family history, past stroke, or my current medications.I am able to understand and consent to participate in the study.I have tried at least 2 antidepressants without success.I am receiving two or more approved additional treatments (not including benzodiazepines).I have been diagnosed with a psychotic disorder during my current depressive episode.I have been diagnosed with major depression, confirmed by a high HAM-D score.My condition did not improve after trying two different types of treatment.I have a neurological condition like epilepsy or severe head trauma.
Research Study Groups:
This trial has the following groups:- Group 1: Open-label TMS
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.